Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico clinical trials (ISCTs), which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine. 

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and ISCTs through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.


Priorities in 2018

→ Continue facilitating dialogue on in silico with regulators and actors around the world and seek opportunities to expand the Alliance geographically;
→ Launch of the new Avicenna Alliance internship scheme;
→ Organisation of the Avicenna Alliance summit in September;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Working group leader:

  • Markus Reiterer
  • Sr. Prin. Materials Scientist, Technical Fellow
  • Science, Technology & Clinical Affairs
  • Medtronic, PLC (Minneapolis, USA)

Avicenna Alliance news

Member of European Parliament Nicola Caputo supports the international cooperation on in silico medicine

MEP Nicola Caputo, from the Alliance of Socialists and Democrats, agreed to sign - along with...

find out more ›

Digital Twin & CM&S to feature in Horizon Europe core text

On 17 April, the European Parliament adopted the partial agreements resulting from interinstitutional negotiations on the two Horizon Europe...

find out more ›

Launch of the MOBILISE-D Project

On 11 April, the project MOBILISE-D, a project funded by the European Innovative Medicines Initiative 2 Joint Undertaking, was launched with the aim to revolutionise...

find out more ›

Show all activites